Qiagen N.V. (QGEN)

Market Cap	9.35B
Revenue (ttm)	1.97B
Net Income (ttm)	92.93M
Shares Out	222.26M
EPS (ttm)	0.41
PE Ratio	101.52
Forward PE	18.81
Dividend	$1.32 (3.14%)
Ex-Dividend Date	Jan 30, 2024

Volume	1,751,238
Open	40.63
Previous Close	40.80
Day's Range	40.49 - 42.42
52-Week Range	39.03 - 47.44
Beta	0.40
Analysts	Buy
Price Target	51.05 (+21.29%)
Earnings Date	Nov 6, 2024

About QGEN

Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.

Analyst Forecast

According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $51.05, which is an increase of 21.29% from the latest price.

Price Target

$51.05

(21.29% upside)

Analyst Consensus: Buy